IMPACT Therapeutics, Inc. Class H
HHKEX:763010.39
HKD
-0.96
(-8.46%)
ISIN
CNE100007LG4
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Sui Xiong Cai
- Full Time Employees
- 89
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- New Bund Times Square Shanghai SH China 200126
- IPO Date
- May 13, 2026
- Website
- impacttherapeutics.com
- Similar Companies
- Business
- IMPACT Therapeutics, Inc. is a China-based biotechnology company focused on the discovery, development, and commercialization of synthetic lethality–based targeted anti-cancer therapeutics, with a clinical-stage portfolio addressing DDR pathways. It operates as a biotechnology company engaged in research, development, and commercialization activities across Asia-Pacific and internationally, aiming to bring precision oncology medicines to patients. Main Products and Services - PARP inhibitors: lead program Senaparib (IMP4297) advanced as a PARP1/2 selective inhibitor, developed for ovarian cancer, prostate cancer, small cell lung cancer, and other indications with ongoing Phase II/III trials; targeted to address homologous recombination repair deficiencies through synthetic lethality mechanisms. - ATR inhibitors: candidate IMP9064 evaluated as a monotherapy in Phase I/II trials for advanced solid tumors, with a DDR-pathway focus on replication stress responses. - WEE1 inhibitors: candidate IMP7068, developed to disrupt cell cycle control in tumors with defective DNA damage response, currently in early-to-mid clinical development. - CNS-penetrant PARP inhibitors: candidates such as IMP1707 designed to cross the blood-brain barrier for central nervous system tumors or lesions with DDR vulnerabilities. - Additional DDR pathway inhibitors: pipeline includes compounds targeting PARP1/2, ATM, CHK1/2, USP1, and other DDR targets; several are in preclinical or early clinical stages (e.g., IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, IMP32). - Research and collaboration services: through in-house discovery platforms and partnerships, the company collaborates with academic and industry entities to advance synthetic lethality targets and identify novel DDR inhibitors. Latest Major Company Changes - Financing and capital structure: completed Series D1 financing to accelerate development of synthetic lethality programs, with a focus on advancing lead DDR assets through clinical development and expanding the portfolio into additional DDR targets. This financing supports pipeline expansion and infrastructural capabilities for global trials. - Pipeline expansion and clinical progression: ongoing advancement of lead PARP inhibitor program into broader oncology indications worldwide, including China, with planned or ongoing Phase II/III trials; concurrent expansion of ATR and WEE1 inhibitor programs into clinical evaluation, signaling a broader DDR-focused strategy. - Strategic expansion and collaborations: strengthening partnerships and potential alliances to accelerate development, manufacturing, and potential out-licensing opportunities for differentiated DDR inhibitors; alignment of research programs toward best-in-class potential within synthetic lethality space. - Corporate positioning: continued emphasis on becoming a global leader in DDR-targeted oncology therapies, with organizational and programmatic updates designed to support expansion into additional markets and regulatory pathways. Additional Context - Industry and segments: biotechnology; oncology; targeted cancer therapies; DNA damage response (DDR)–based therapeutics; small-molecule discovery and development. - Target markets and customers: global oncology patients; pharmaceutical partners and academic collaborators; healthcare systems in China, the United States, Europe, and other regions seeking precision anti-cancer medicines. - Geographic operations: headquarters in China with development and commercialization activities across China and international markets; potential collaborations and trials in multiple regions depending on program stage. - Founding year and headquarters: founded in the 2010s with headquarters in China ( Beijing/Shanghai area as commonly stated in corporate descriptions; exact city may vary by source). - Subsidiaries/parent: operates as an independent clinical-stage biotech with potential regional subsidiaries or affiliates supporting China-focused commercialization and international partnerships. Note: information reflects public disclosures on core programs, financing events, and strategic activity through recent years. Please verify the latest regulatory filings and press releases for the most current specifics on trial statuses, financial rounds, and geographic coverage.